Sprache: Englisch
Verlag: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 25,83
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Sprache: Englisch
Verlag: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 33,28
Anzahl: 2 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 96 pages. 6.00x0.22x9.00 inches. In Stock.
Sprache: Englisch
Verlag: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. 2025. paperback. . . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Anbieter: Kennys Bookstore, Olney, MD, USA
Zustand: New. 2022. Paperback. . . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
Sprache: Englisch
Verlag: Cambridge University Press Dez 2022, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Neuware - The tension between innovation and financialisation is central to the business corporation. Innovation entails a 'retain-and-reinvest' allocation regime that can form a foundation for stable and equitable economic growth. Driven by shareholder-value ideology, financialisation entails a shift to 'downsize-and-distribute'. This Element investigates this tension in global pharmaceuticals, focusing on the two leading UK companies AstraZeneca and GlaxoSmithKline. In the 2000s both adopted US-style governance, including stock buybacks and stock-based executive pay. Over the past decade, however, first AstraZeneca and then GlaxoSmithKline transitioned to innovation. Critical was the cessation of buybacks to refocus capabilities on investing in an innovative drugs pipeline. Enabling this shift were UK corporate-governance institutions that mitigated US-style shareholder-value maximisation. Reinventing capitalism for the sake of stable and equitable economic growth means eliminating value destruction caused by financialisation and supporting value creation through collective and cumulative innovation. This title is also available as Open Access on Cambridge Core.
Sprache: Englisch
Verlag: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Anbieter: Kennys Bookstore, Olney, MD, USA
EUR 102,38
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New.
Sprache: Englisch
Verlag: Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 112,38
Anzahl: 2 verfügbar
In den WarenkorbHardcover. Zustand: Brand New. 96 pages. 6.00x0.25x9.00 inches. In Stock.